Role of epidermal growth factor receptor in breast cancer

Breast Cancer Research and Treatment

Volumn 136, Issue 2, 2012, Pages 331-345

  Masuda, Hiroko ^a   Zhang, Dongwei ^a   Bartholomeusz, Chandra ^a   Doihara, Hiroyoshi ^a,b   Hortobagyi, Gabriel N ^a   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Breast cancer; EGFR; Inflammatory breast cancer; Targeted therapy; Triple negative breast cancer

Indexed keywords

ADERBASIB; AE 37; AFATINIB; ANTINEOPLASTIC AGENT; AZD 4769; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; ESTROGEN RECEPTOR; FLUOROURACIL; GA 201; GEFITINIB; IRINOTECAN; LAPATINIB; LAPULEUCEL T; MATUZUMAB; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PANITUMUMAB; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER PROGNOSIS; CHEMOSENSITIVITY; DRUG EFFICACY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INFLAMMATORY BREAST CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASMS, BASAL CELL; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84868208974     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2289-9     Document Type: Review

References (91)

1. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799
2. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL (1987) Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1:1398-1402
3. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
4. Burness ML, Grushko TA, Olopade OI (2010) Epidermal growth factor receptor in triple-negative and basal-like breast cancer: Promising clinical target or only a marker? Cancer J 16:23-32
5. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25-32
6. Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N et al (1989) Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance. Int J Cancer 43:201-208
7. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P et al (1984) Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521-527
8. Schulze WX, Deng L, Mann M (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1:2005-2008
9. Eccles SA (2011) The epidermal growth factor receptor/Erb-B/ HER family in normal and malignant breast biology. Int J Dev Biol 55:685-696
10. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P et al (1998) Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: A different perspective in epithelial biology. Proc Natl Acad Sci USA. 95:14821-14826
11. Lurje G, Lenz HJ (2009) EGFR signaling and drug discovery. Oncology 77:400-410
12. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S (1993) Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study. Pathologica 85:637-644
13. Jin Q, Esteva FJ (2008) Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13:485-498
14. Menard S, Balsari A, Casalini P, Tagliabue E, Campiglio M, Bufalino R et al (2002) HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8:520-525
15. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M et al (2004) Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314-322
16. Giaccone G (2005) Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23:3235-3242
17. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H et al (2004) Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64:8534-8540
18. Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M (1988) Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 48:161-164
19. Spyratos F, Delarue JC, Andrieu C, Lidereau R, Champeme MH, Hacene K et al (1990) Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17:83-89
20. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T (2005) EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29:633-639
21. Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K et al (2006) EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 209:445-453
22. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M et al (2005) EGFR gene amplification in breast cancer: Correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18:1027-1033
23. Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM et al (2005) Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer 92:1922-1926
24. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U et al (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:6829-6837
25. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 6:279-286
26. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082-1089
27. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
28. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500
29. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N et al (2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24:5034-5042
30. Sainsbury JR, Nicholson S, Angus B, Farndon JR, Malcolm AJ, Harris AL (1988) Epidermal growth factor receptor status of histological sub-types of breast cancer. Br J Cancer 58:458-460
31. Ozawa S, Ueda M, Ando N, Shimizu N, Abe O (1989) Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 63:2169-2173
32. Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A et al (2009) Invasive ductal carcinoma of the breast with the "triple- negative" phenotype: Prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116:317-328
33. Radisky DC (2005) Epithelial-mesenchymal transition. J Cell Sci 118:4325-4326
34. Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776-1784
35. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454
36. Thompson EW, Newgreen DF, Tarin D (2005) Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res 65:5991-5995 discussion 5
37. Micalizzi DS, Ford HL (2009) Epithelial-mesenchymal transition in development and cancer. Future Oncol 5:1129-1143
38. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N et al (2009) Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28:2940-2947
39. Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D et al (2007) Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6:532-541
40. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P et al (2009) Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 15:6639-6648
41. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV et al (2009) RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell 35:511-522
42. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL (2004) Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 6:603-610
43. Santamaria PG, Nebreda AR (2010) Deconstructing ERK signaling in tumorigenesis. Mol Cell 38:3-5
44. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434
45. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
46. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N (2009) Triple-negative breast cancer-current status and future directions. Ann Oncol 20:1913-1927
47. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P et al (2008) How basal are triple-negative breast cancers? Int J Cancer 123:236-240
48. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767
49. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, Macbeath G et al (2012) Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149:780-794
50. Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H (2009) Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): Analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 11:R9
51. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA et al (2011) International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment. Ann Oncol 22:515-523
52. Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A et al (2007) Expression of growth factor and chemokine receptors: New insights in the biology of inflammatory breast cancer. Ann Oncol 18:1021-1029
53. Mueller KL, Yang ZQ, Haddad R, Ethier SP, Boerner JL (2010) EGFR/Met association regulates EGFR TKI resistance in breast cancer. J Mol Signal 5:8
54. Baillo A, Giroux C, Ethier SP (2011) Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer. J Cell Physiol 226:2691-2701
55. Baselga J (2006) Targeting tyrosine kinases in cancer: The second wave. Science 312:1175-1178
56. Wieduwilt MJ, Moasser MM (2008) The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cell Mol Life Sci 65:1566-1584
57. Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565
58. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Luck HJ et al (2005) A multicentre phase II study on gefitinib in taxane-and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89:165-172
59. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445-2459
60. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V et al (2005) Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 23:5323-5333
61. Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP (2009) Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 115:115-121
62. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX et al TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. Published online on June 4, 2012
63. Khambata-Ford S, O'Shaughnessy J, Brickman D, et al (2010) Candidate predictive biomarkers of cetuximab benefit in triplenegative breast cancer. J Clin Oncol 28(suppl): Abstr 1056
64. Baselga J, Steemmer S, Pego A, et al (2010) Cetuximab ? cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: Results of the randomized phase II BALI-1 trial. Cancer Res 70:24(Suppl) SABCS10-PD01-01
65. Nabholtz J, Weber B, Mouret-Reynier M et al (2011) Panitumumab in combination with FEC100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study. J Clin Oncol 29(suppl): Abstr e11574
66. Corkery B, Crown J, Clynes M, O'Donovan N (2009) Epidermal growth factor receptor as a potential therapeutic target in triplenegative breast cancer. Ann Oncol 20:862-867
67. Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305-5313
68. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P et al (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26:1066-1072
69. Schuler M H, Uttenreuther-Fischer MM, Piccart-Gebhart MJ et al (2010) BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies. J Clin Oncol 28(suppl): Abstr 1065
70. Erlichman C, Hidalgo M, Boni JP et al (2006) Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 24:2252-2260
71. Burstein HJ, Storniolo AM, Franco S et al (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19:1068-1074
72. Calvo E, Tolcher AW, Hammond LA et al (2004) Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: A phase I pharmacokinetic and food effect study. Clin Cancer Res 10:7112-7120
73. Nemunaitis J, Eiseman I, Cunningham C et al (2005) Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 11:3846-3853
74. Yap TA, Vidal L, Adam J et al (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965-3972
75. Polychronis A, Sinnett HD, Hadjiminas D et al (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growthfactor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6:383-391
76. Smith IE, Walsh G, Skene A et al (2007) A phase II placebocontrolled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 25:3816-3822
77. Mauriac L, Cameron D, Dirix L et al (2008) Results of randomized phase II trial combining Iressa (gefitinib) and Arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021. S6133
78. Cristofanilli M, Valero V, Mangalik A et al (2008) A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefitinib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR?) metastatic breast cancer (MBC). J Clin Oncol 26(May 20 suppl): Abstr 1012
79. Dennison SK, Jacobs SA, Wilson JW et al (2007) A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Invest New Drugs 25:545-551
80. Arteaga CL, O'Neill A, Moulder SL et al (2008) A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 14: 6277-6283
81. Mayer I, Granja N, Shyr Y et al (2006) A phase II trial of letrozole plus erlotinib in post menopausal women with hormonesensitive metastatic breast cancer (MBC): Preliminary results of toxicities and correlative studies. S4052
82. Twelves C, Trigo JM, Jones R et al (2008) Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study. Eur J Cancer 44:419-426
83. Venturini M, Catzeddu T, Del L et al (2004) Erlotinib given sequentially to capecitabine and vinorelbine as first-second line chemotherapy in metastatic breast cancer patients. A dose finding study. J Clin Oncol 22(suppl): Abstr 834
84. Kaur H, Silverman P, Singh D et al (2006) Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC). J Clin Oncol 24(June 20 suppl): Abstr 10623
85. Dickler MN, Rugo HS, Eberle CA et al (2008) A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 14:7878-7883
86. Beeram M, De Bono JS, Pamaik A et al (2005) Phase I and pharmacokinetics (PK) of combined erbB1 and erbB2 blockade with OSI-774 (Erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with advanced solid tumors. S2034
87. Johnston S, Pippen J Jr, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546
88. Di Leo A, Gomez HL, Aziz Z et al (2008) Phase III, doubleblind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544-5552
89. Garland LL, Hidalgo M, Mendelson DS et al (2006) A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12:4274-4282
90. Modi S, D'Andrea G, Norton L et al (2006) A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 7:270-277
91. Rivera P, Filleron T, Gladieff L et al (2011) Efficacy of cetuximab plus platinum agent in advanced, triple-negative breast carcinoma: Results of a retrospective analysis. J Clin Oncol 29(suppl): Abstr e11581